文献速递心脑血管急症

及时且适当地给予吸入氩气可改善tMCAO小鼠的结局:一项对照、随机、双盲动物研究

Timely and Appropriate Administration of Inhaled Argon Provides Better Outcomes for tMCAO Mice: A Controlled, Randomized, and Double-Blind Animal Study.
PubMed 文献 · Neurocrit Care · 2022-02-08
一句话结论小鼠tMCAO模型显示,缺血期(卒中后1小时)开始吸入氩气并采用较短疗程(1或3小时)及较高浓度,可改善梗死体积与神经功能,作者认为这可为氩气临床研究提供参考。

该研究为对照、随机、双盲动物实验,采用成年ICR小鼠建立中度(1.5小时)或重度(3小时)短暂性大脑中动脉闭塞(tMCAO)模型,卒中后1小时随机给予不同吸入氩气(iAr)方案或空气。结果显示,与仅tMCAO组相比,卒中后1小时(缺血期)给予iAr可显著改善病灶体积(p<0.0001)和神经功能结局(总体p<0.0001;局灶p<0.0001)。短期氩气治疗(1或3小时)较24小时吸入显著改善梗死体积(1 vs 24小时,p<0.0001;3 vs 24小时,p<0.0001)。iAr浓度是改善局灶神经功能的关键因素,浓度越高效果越好;氩气对梗死体积、神经功能缺损、体重恢复和水肿均有显著神经保护作用(均p<0.0001),在中度卒中尤为明显。作者认为这些发现可为氩气作为神经保护剂的临床应用及急性缺血性卒中的临床试验提供重要参考。

要点

  • 小鼠tMCAO后1小时(缺血期)开始吸入氩气,较仅tMCAO组显著改善病灶体积(p<0.0001)和神经功能结局(总体p<0.0001;局灶p<0.0001)。
  • 短期氩气治疗(1或3小时)较24小时吸入显著改善梗死体积(1 vs 24小时,p<0.0001;3 vs 24小时,p<0.0001)。
  • 吸入氩气浓度是改善局灶神经功能的关键因素,较高浓度显示更好效果。
  • 氩气对梗死体积、神经功能缺损(总体p<0.0001;局灶p<0.0001)、体重恢复(p<0.0001)和水肿(p<0.0001)均有显著神经保护作用,尤其中度卒中。
  • 作者认为及时且适当疗程的吸入氩气可提供最佳神经功能结局和最小梗死体积,并可能为氩气临床转化提供参考。

适用人群与场景

  • 成年ICR(Institute of Cancer Research)小鼠,随机接受假手术、中度(1.5小时)或重度(3小时)短暂性大脑中动脉闭塞(tMCAO)。

处置流程与药物剂量

  • tMCAO后1小时随机给予不同吸入氩气方案或空气,治疗期间采用双盲法评估总体和局灶神经功能缺损评分。
  • 吸入氩气浓度是改善局灶神经功能的关键因素,较高浓度显示更好效果;短期治疗(1或3小时)优于24小时吸入。

研究设计与关键结果

  • 研究类型:对照、随机、双盲动物实验;样本量:成年ICR小鼠(具体例数原文未报告);人群:中度(1.5小时)或重度(3小时)tMCAO小鼠模型。
  • 与仅tMCAO组相比,卒中后1小时(缺血期)给予iAr组病灶体积显著改善(p<0.0001),神经功能结局显著改善(总体p<0.0001;局灶p<0.0001)。
  • 短期氩气治疗(1或3小时)较24小时吸入显著改善梗死体积(1 vs 24小时,p<0.0001;3 vs 24小时,p<0.0001)。
  • 吸入氩气浓度是改善局灶神经功能的关键因素,较高浓度显示更好效果。
  • 氩气对梗死体积(p<0.0001)、神经功能缺损(总体p<0.0001;局灶p<0.0001)、体重恢复(p<0.0001)和水肿(p<0.0001)均有显著神经保护作用,尤其中度卒中。
  • 结论:缺血期及时给予iAr显示最佳神经功能结局和最小梗死体积;适当疗程对更好神经保护效果重要。

证据类型、等级与局限

  • 证据类型:对照、随机、双盲动物实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些发现可能为使用氩气作为神经保护剂以及推进急性缺血性卒中的临床试验提供重要参考。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Inhaled argon (iAr) has shown promising therapeutic efficacy for acute ischemic stroke and has exhibited impressive advantages over other inert gases as a neuroprotective agent. However, the optimal dose, duration, and time point of iAr for acute ischemic stroke are unknown. Here, we explored variable iAr schedules and evaluated the neuroprotective effects of acute iAr administration on lesion volume, brain edema, and neurological function in a mouse model of cerebral ischemic/reperfusion injury.

METHODS: Adult ICR (Institute of Cancer Research) mice were randomly subjected to sham, moderate (1.5 h), or severe (3 h) transient middle cerebral artery occlusion (tMCAO). One hour after tMCAO, the mice were randomized to variable iAr protocols or air. General and focal deficit scores were assessed during double-blind treatment. Infarct volume, overall recovery, and brain edema were analyzed 24 h after cerebral ischemic/reperfusion injury.

RESULTS: Compared with those in the tMCAO-only group, lesion volume (p < 0.0001) and neurologic outcome (general, p < 0.0001; focal, p < 0.0001) were significantly improved in the group administered iAr 1 h after stroke onset (during ischemia). Short-term argon treatment (1 or 3 h) significantly improved the infarct volume (1 vs. 24 h, p < 0.0001; 3 vs. 24 h, p < 0.0001) compared with argon inhalation for 24 h. The concentration of iAr was confirmed to be a key factor in improving focal neurological outcomes relative to that in the tMCAO group, with higher concentrations of iAr showing better effects. Additionally, even though ischemia research has shown an increase in cerebral damage proportional to the ischemia time, argon administration showed significant neuroprotective effects on infarct volume (p < 0.0001), neurological deficits (general, p < 0.0001; focal, p < 0.0001), weight recovery (p < 0.0001), and edema (p < 0.0001) in general, particularly in moderate stroke.

CONCLUSIONS: Timely iAr administration during ischemia showed optimal neurological outcomes and minimal infarct volumes. Moreover, an appropriate duration of argon administration was important for better neuroprotective efficacy. These findings may provide vital guidance for using argon as a neuroprotective agent and moving to clinical trials in acute ischemic stroke.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. He J, Xue K, Liu J, et al. Timely and Appropriate Administration of Inhaled Argon Provides Better Outcomes for tMCAO Mice: A Controlled, Randomized, and Double-Blind Animal Study. Neurocrit Care. 2022. PMID: 35137354. doi:10.1007/s12028-022-01448-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。